Cumberland Pharmaceuticals (NASDAQ:CPIX) Stock Passes Above 200-Day Moving Average - Should You Sell?

Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX - Get Free Report)'s stock price passed above its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $3.79 and traded as high as $5.88. Cumberland Pharmaceuticals shares last traded at $5.78, with a volume of 33,908 shares traded.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen raised Cumberland Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research report on Thursday, May 8th.

Cumberland Pharmaceuticals Trading Down 2.4%

The firm has a 50 day simple moving average of $4.76 and a 200 day simple moving average of $3.80. The company has a current ratio of 1.13, a quick ratio of 0.99 and a debt-to-equity ratio of 0.41. The firm has a market capitalization of $80.79 million, a PE ratio of -7.01 and a beta of -0.35.

Cumberland Pharmaceuticals (NASDAQ:CPIX - Get Free Report) last issued its earnings results on Tuesday, May 6th. The specialty pharmaceutical company reported $0.15 EPS for the quarter. Cumberland Pharmaceuticals had a negative return on equity of 9.50% and a negative net margin of 29.54%.

Hedge Funds Weigh In On Cumberland Pharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of the company. Two Sigma Investments LP boosted its stake in shares of Cumberland Pharmaceuticals by 94.3% in the 4th quarter. Two Sigma Investments LP now owns 37,649 shares of the specialty pharmaceutical company's stock worth $89,000 after buying an additional 18,271 shares during the last quarter. Walleye Capital LLC purchased a new position in shares of Cumberland Pharmaceuticals in the 1st quarter worth $298,000. Informed Momentum Co LLC purchased a new position in shares of Cumberland Pharmaceuticals in the 1st quarter worth $304,000. Adage Capital Partners GP L.L.C. purchased a new position in shares of Cumberland Pharmaceuticals in the 1st quarter worth $634,000. Finally, Berkshire Asset Management LLC PA purchased a new position in shares of Cumberland Pharmaceuticals in the 1st quarter worth $692,000. 15.51% of the stock is currently owned by hedge funds and other institutional investors.

About Cumberland Pharmaceuticals

Cumberland Pharmaceuticals Inc, a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.